A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Status
- RECRUITING
- Phase
- PHASE2
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
- Status
- WITHDRAWN
- Phase
- PHASE1
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
- Status
- COMPLETED
- Phase
- PHASE1
Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Isolated Hepatic Perfusion in Combination With Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastases
- Status
- COMPLETED
- Phase
- PHASE1
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant Immunotherapy in Brain Metastases
- Status
- TERMINATED
- Phase
- PHASE2
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
FOLFOX + Immunotherapy With Intrahepatic Oxaliplatin for Patients With Metastatic Colorectal Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2